CytoDyn Inc. received a $5 million private investment to support the clinical development of leronlimab, a monoclonal antibody targeting the CCR5 receptor, for colorectal cancer and other solid tumors like triple-negative breast cancer. The funds will help expand research based on promising data from the CLOVER study and explore leronlimab's use in earlier treatment stages and additional cancers such as pancreatic cancer and glioblastoma. This investment reflects confidence in CytoDyn's recent clinical findings and supports ongoing efforts to develop new cancer therapies.
CytoDyn's $5 million private investment announcement comes with this health sector snapshot from Pluang as of Nov 12, 2026 20:12 WIB: Out of 150 priced US health stocks, 82 advanced while 64 declined. Notable movers include INO at USD 1.42 with a 3.73% drop and a typical hold time of 41 days, MRNA at USD 239.52 down 3.69%, and RXRX at USD 3.46 down 3.62% but with 100% buy order activity. The most notable figure is the 82 stocks that rose today.
Interlink Electronics announced a 3.4% revenue increase to $3.06 million for Q3 2026 and a 9.6% rise to $9.9 million for the first nine months of 2026, driven by higher shipments of force-sensing and gas-sensor products. The company reported a net lo...
ALS Canada, with renewed funding from TD Bank, is advancing its national strategy for ALS genetics to enhance access to genetic information, counselling, and care for Canadians affected by or at risk of ALS. This builds on the 2024 pilot of the first...
The Canadian ALS Society has renewed funding from TD Bank to expand its national genetics strategy for ALS, improving access to genetic information, counseling, and care for those affected or at risk. This initiative builds on a pilot project that cr...
CollPlant Biotechnologies will change its Nasdaq ticker from CLGN to OPHI starting November 13, 2026, reflecting its strategic shift toward photonic computing through its subsidiary LightSolver. This move highlights CollPlant's focus on developing Li...
Evaxion, a clinical-stage TechBio company, has released its financial calendar for 2027, outlining important dates for business updates and financial results. Key events include the full year 2026 results on March 4, the Annual General Meeting on Apr...
